Travere Therapeutics, Inc. $TVTX Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 2.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,557,196 shares of the company’s stock after selling 36,988 shares during the quarter. Travere Therapeutics makes up about 1.5% of Emerald Advisers LLC’s investment portfolio, making the stock its 12th biggest position. Emerald Advisers LLC’s holdings in Travere Therapeutics were worth $46,264,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in TVTX. Fifth Third Bancorp acquired a new position in Travere Therapeutics in the first quarter valued at $35,000. Hsbc Holdings PLC purchased a new position in Travere Therapeutics during the first quarter worth about $11,788,000. Burney Co. acquired a new stake in Travere Therapeutics in the 1st quarter worth about $1,180,000. Stephens Investment Management Group LLC boosted its stake in Travere Therapeutics by 4.5% in the 1st quarter. Stephens Investment Management Group LLC now owns 1,798,466 shares of the company’s stock worth $53,432,000 after buying an additional 76,843 shares during the last quarter. Finally, Private Advisor Group LLC grew its holdings in Travere Therapeutics by 24.3% in the 1st quarter. Private Advisor Group LLC now owns 15,422 shares of the company’s stock valued at $458,000 after buying an additional 3,010 shares during the period.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $56.29 on Tuesday. The firm has a market capitalization of $5.23 billion, a PE ratio of -244.73 and a beta of 1.10. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 3.08. The business has a 50-day moving average of $49.97 and a two-hundred day moving average of $38.44. Travere Therapeutics, Inc. has a 12 month low of $15.03 and a 12 month high of $60.10.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same period in the previous year, the company posted ($0.47) EPS. The company’s revenue was up 55.6% compared to the same quarter last year. As a group, research analysts forecast that Travere Therapeutics, Inc. will post -0.25 earnings per share for the current year.

Insider Transactions at Travere Therapeutics

In other Travere Therapeutics news, insider Jula Inrig sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $45.00, for a total transaction of $900,000.00. Following the completion of the sale, the insider directly owned 111,473 shares in the company, valued at $5,016,285. The trade was a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric M. Dube sold 64,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $41.09, for a total transaction of $2,629,760.00. Following the completion of the sale, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at $17,787,285.74. The trade was a 12.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 195,330 shares of company stock valued at $8,517,486 in the last three months. 4.44% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Guggenheim upped their price objective on shares of Travere Therapeutics from $56.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Weiss Ratings cut shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Citigroup boosted their target price on shares of Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 15th. JPMorgan Chase & Co. dropped their price target on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, March 25th. Finally, Wall Street Zen downgraded shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $52.08.

Travere Therapeutics Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.